MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/480/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/480/0.01/20.09.24 Share Price

DE000ME4N3L3

Real-time Bid/Ask 06:08:02 02/07/2024 pm IST
0.24 ^EUR / 0.26 ^EUR	+17.37%

Current month	-10.88%
1 month	+21.02%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/480/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	06:04pm	BU
Vertex to Announce Second Quarter 2024 Financial Results on August 1	02/07	BU
Verve Therapeutics, Inc. Announces Board Appointments	28/06	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	27/06	MT

More news

Quotes 5-day view

Date	Price	Change
02/24/02	0.229	+7.51%
01/24/01	0.213	-10.88%
28/24/28	0.239	+3.46%
27/24/27	0.231	+0.43%
26/24/26	0.23	-0.43%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 05:29 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4N3L
ISIN	DE000ME4N3L3
Date issued	05/12/2023
Strike	480 $
Maturity	20/09/2024 (80 Days)
Parity	100 : 1
Emission price	0.1 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.35 €
Lowest since issue	0.075 €
Delta	0.51x
Omega	9.516
Premium	7.21x
Gearing	18.68x
Moneyness	0.9818
Difference Strike	8.75 $
Difference Strike %	+1.82%
Spread	0.01 €
Spread %	4.17%
Theoretical value	0.2350
Implied Volatility	30.36 %
Total Loss Probability	54.73 %
Intrinsic value	0.000000
Present value	0.2350
Break even	505.22 €
Theta	-0.01x
Vega	0.01x
Rho	0x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.2 USD

Average target price

468.3 USD

Spread / Average Target

-0.63%

Consensus